Author Correction: Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in Japan.
Free full text in Europe PMC
Abstract
Free full text
Author Correction: Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in Japan
1 Correction to: Scientific Reports 10.1038/s41598-024-60011-y, published online 20 April 2024
The original version of this Article contained errors in Tables 1 and 2 where the number and percentage of comorbidity reported were incorrect.
Table 1
Baseline characteristics in all patients, including new and non-new users of heart failure treatment. SD standard deviation, BNP brain natriuretic peptide, NT-proBNP N-terminal pro-brain natriuretic peptide, ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin-receptor blocker, MRA mineralocorticoid receptor antagonist, SGLT-2i sodium-glucose cotransporter-2 inhibitor, HF heart failure. *Occurred within one year before the index HF hospitalization. **Used during the period of 183 days before the index date.
|
Overall
(N  =9091)
|
New users
(N =2735)
|
Non-new users (N=6356)
| |
|---|---|---|---|
| Age (years) | |||
| Mean±SD | 77.6±10.0 | 77.4±10.3 | 77.6±9.9 |
| Age group, n (%) | |||
| <40 | 56 (0.6) | 19 (0.7) | 37 (0.6) |
| 40–64 | 841 (9.3) | 253 (9.3) | 588 (9.3) |
| 65–74 | 1827 (20.1) | 561 (20.5) | 1266 (19.9) |
| ≥75 | 6367 (70.0) | 1902 (69.5) | 4465 (70.2) |
| Gender, male, n (%) | 5007 (55.1) | 1477 (54.0) | 3530 (55.5) |
| BNP (pg/mL) | |||
| Patients with recorded BNP values, n (%) | 6534 (71.9) | 2008 (73.4) | 4526 (71.2) |
| Mean±SD | 336.6±509.9 | 374.9±499.3 | 319.7±513.7 |
| BNP/NT-proBNP category, n (%) | |||
| BNP≤100 or NT-proBNP≤400 pg/mL | 2302 (25.3) | 541 (19.8) | 1761 (27.7) |
| 100<BNP≤200 or 400<NT-proBNP≤900 pg/mL | 1366 (15.0) | 413 (15.1) | 953 (15.0) |
| 200<BNP≤300 or 900<NT-proBNP≤2000 pg/mL | 991 (10.9) | 340 (12.4) | 651 (10.2) |
| BNP>300 or NT-proBNP≥2000 pg/mL | 2548 (28.0) | 913 (33.4) | 1635 (25.7) |
| Missing | 1884 (20.7) | 528 (19.3) | 1356 (21.3) |
| Comorbidity, n (%) | |||
| Hypertension | 5464 (60.1) | 1540 (56.3) | 3924 (61.7) |
| Chronic kidney disease | 5005 (55.1) | 1489 (54.4) | 3516 (55.3) |
| Ischemic heart disease | 3721 (40.9) | 1044 (38.2) | 2677 (42.1) |
| Atrial fibrillation | 2584 (28.4) | 779 (28.5) | 1805 (28.4) |
| Diabetes mellitus | 2352 (25.9) | 656 (24.0) | 1696 (26.7) |
| Stroke | 1323 (14.6) | 387 (14.1) | 936 (14.7) |
| Myocardial infarction | 1301 (14.3) | 319 (11.7) | 982 (15.4) |
| Chronic obstructive pulmonary disease | 1096 (12.1) | 297 (10.9) | 799 (12.6) |
| Anemia | 2145 (23.6) | 576 (21.1) | 1569 (24.7) |
| Hyperkalemia | 692 (7.6) | 199 (7.3) | 493 (7.8) |
| Hypotension | 244 (2.7) | 38 (1.4) | 206 (3.2) |
| Cardiovascular procedure, n (%) | |||
| Cardiac resynchronization therapy | 215 (2.4) | 65 (2.4) | 150 (2.4) |
| Implantable cardioverter defibrillator | 41 (0.5) | 16 (0.6) | 25 (0.4) |
| Having a history of prior hospitalization for HF*, n (%) | 1372 (15.1) | 290 (10.6) | 1082 (17.0) |
| HF treatments before the index date**, n (%) | |||
| ACEi | 1291 (14.2) | 376 (13.7) | 915 (14.4) |
| ARB | 3519 (38.7) | 1075 (39.3) | 2444 (38.5) |
| MRA | 1765 (19.4) | 461 (16.9) | 1304 (20.5) |
| Beta-blockers | 3801 (41.8) | 1058 (38.7) | 2743 (43.2) |
| SGLT-2i | 198 (2.2) | 59 (2.2) | 139 (2.2) |
| Digoxin/digitoxin | 424 (4.7) | 141 (5.2) | 283 (4.5) |
| Loop diuretics | 4706 (51.8) | 1455 (53.2) | 3251 (51.1) |
| Thiazide diuretics | 668 (7.3) | 223 (8.2) | 445 (7.0) |
| Tolvaptan | 718 (7.9) | 146 (5.3) | 572 (9.0) |
Table 2
Characteristics of new users based on different heart failure medication classes. SD standard deviation, BNP brain natriuretic peptide, NT-proBNP N-terminal pro-brain natriuretic peptide, ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin-receptor blocker, MRA mineralocorticoid receptor antagonist, SGLT-2i sodium-glucose cotransporter-2 inhibitor, HF heart failure. *Used during the period of 183 days before the index date.
|
ACEi
(N =357)
|
ARB
(N =304)
|
MRA
(N =773)
|
Beta-blockers (N=695)
|
SGLT-2i
(N =109)
|
Digoxin/digitoxin (N=91)
|
Loop diuretics (N=725)
|
Thiazide diuretics (N=198)
|
Tolvaptan
(N =709)
| |
|---|---|---|---|---|---|---|---|---|---|
| Age (years) | |||||||||
| Mean±SD | 76.5±10.6 | 76.0±11.1 | 78.0±9.9 | 75.7±11.4 | 71.3±11.6 | 77.2±9.4 | 78.1±9.4 | 78.5±9.0 | 78.7±9.3 |
| Gender, male, n (%) | 212 (59.4) | 151 (49.7) | 427 (55.2) | 370 (53.2) | 71 (65.1) | 43 (47.3) | 368 (50.8) | 102 (51.5) | 401 (56.6) |
| BNP (pg/mL) | |||||||||
Patients with recorded BNP values, n (%) | 263 (73.7) | 222 (73.0) | 561 (72.6) | 512 (73.7) | 86 (78.9) | 76 (83.5) | 470 (64.8) | 152 (76.8) | 539 (76.0) |
| Mean±SD | 468.0±693.6 | 413.0±551.6 | 410.1±512.1 | 396.3±611.1 | 386.7±432.0 | 368.0±342.5 | 253.2±275.0 | 371.8±407.9 | 422.3±492.4 |
| BNP/NT-proBNP category, n (%) | |||||||||
BNP NT-proBNP | 48 (13.4) | 60 (19.7) | 124 (16.0) | 157 (22.6) | 24 (22.0) | 13 (14.3) | 181 (25.0) | 39 (19.7) | 108 (15.2) |
100 proBNP pg/mL | 60 (16.8) | 47 (15.5) | 120 (15.5) | 100 (14.4) | 18 (16.5) | 16 (17.6) | 111 (15.3) | 25 (12.6) | 95 (13.4) |
200 proBNP pg/mL | 36 (10.1) | 33 (10.9) | 101 (13.1) | 80 (11.5) | 15 (13.8) | 14 (15.4) | 67 (9.2) | 30 (15.2) | 106 (15.0) |
BNP NT-proBNP | 146 (40.9) | 102 (33.6) | 276 (35.7) | 220 (31.7) | 35 (32.1) | 38 (41.8) | 160 (22.1) | 78 (39.4) | 284 (40.1) |
| Missing | 67 (18.8) | 62 (20.4) | 152 (19.7) | 138 (19.9) | 17 (15.6) | 10 (11.0) | 206 (28.4) | 26 (13.1) | 116 (16.4) |
| Comorbidity, n (%) | |||||||||
| Hypertension | 199 (55.7) | 180 (59.2) | 422 (54.6) | 363 (52.2) | 56 (51.4) | 56 (61.5) | 395 (54.5) | 119 (60.1) | 399 (56.3) |
| Chronic kidney disease | 168 (47.1) | 163 (53.6) | 360 (46.6) | 359 (55.5) | 69 (63.3) | 54 (59.3) | 308 (42.5) | 119 (60.1) | 467 (65.9) |
Ischemic heart disease | 144 (40.3) | 113 (37.2) | 295 (38.2) | 264 (38.0) | 47 (43.1) | 33 (36.3) | 250 (34.5) | 77 (38.9) | 243 (34.3) |
| Atrial fibrillation | 115 (32.2) | 82 (27.0) | 238 (30.8) | 157 (22.6) | 23 (21.1) | 54 (59.3) | 166 (22.9) | 45 (22.7) | 227 (32.0) |
| Diabetes mellitus | 73 (20.4) | 63 (20.7) | 172 (22.3) | 171 (24.6) | 50 (45.9) | 22 (24.2) | 175 (24.1) | 54 (27.3) | 166 (23.4) |
| Stroke | 57 (16.0) | 42 (13.8) | 101 (13.1) | 93 (13.4) | 10 (9.2) | 13 (14.3) | 119 (16.4) | 21 (10.6) | 89 (12.6) |
| Myocardial infarction | 54 (15.1) | 33 (10.9) | 98 (12.7) | 66 (9.5) | 14 (12.8) | 12 (13.2) | 78 (10.8) | 18 (9.1) | 79 (11.1) |
| Chronic obstructive pulmonary disease | 43 (12.0) | 28 (9.2) | 86 (11.1) | 63 (9.1) | 5 (4.6) | 9 (9.9) | 66 (9.1) | 20 (10.1) | 83 (11.7) |
| Anemia | 76 (21.3) | 68 (22.4) | 152 (19.7) | 117 (16.8) | 8 (7.3) | 16 (17.6) | 121 (16.7) | 40 (20.2) | 182 (25.7) |
| Hyperkalemia | 24 (6.7) | 22 (7.2) | 31 (4.0) | 50 (7.2) | 4 (3.7) | 4 (4.4) | 36 (5.0) | 25 (12.6) | 70 (9.9) |
| Hypotension | 5 (1.4) | 4 (1.3) | 10 (1.3) | 12 (1.7) | 0 (0) | 1 (1.1) | 6 (0.8) | 2 (1.0) | 13 (1.8) |
| HF treatments before the index date*, n (%) | |||||||||
| ACEi | 0 (0) | 66 (21.7) | 104 (13.5) | 73 (10.5) | 13 (11.9) | 17 (18.7) | 91 (12.6) | 23 (11.6) | 112 (15.8) |
| ARB | 122 (34.2) | 0 (0) | 298 (38.6) | 308 (44.3) | 57 (52.3) | 30 (33.0) | 352 (48.6) | 101 (51.0) | 294 (41.5) |
| MRA | 72 (20.2) | 48 (15.8) | 0 (0) | 110 (15.8) | 23 (21.1) | 31 (34.1) | 61 (8.4) | 40 (20.2) | 196 (27.6) |
| Beta-blockers | 152 (42.6) | 114 (37.5) | 325 (42.0) | 0 (0) | 54 (49.5) | 47 (51.6) | 313 (43.2) | 79 (39.9) | 346 (48.8) |
| SGLT-2i | 10 (2.8) | 6 (2.0) | 16 (2.1) | 19 (2.7) | 0 (0) | 4 (4.4) | 15 (2.1) | 6 (3.0) | 11 (1.6) |
| Digoxin/digitoxin | 16 (4.5) | 9 (3.0) | 45 (5.8) | 32 (4.6) | 4 (3.7) | 0 (0) | 33 (4.6) | 7 (3.5) | 41 (5.8) |
| Loop diuretics | 198 (55.5) | 178 (58.6) | 439 (56.8) | 352 (50.6) | 69 (63.3) | 61 (67.0) | 0 (0) | 135 (68.2) | 532 (75.0) |
| Thiazide diuretics | 25 (7.0) | 18 (5.9) | 55 (7.1) | 57 (8.2) | 9 (8.3) | 9 (9.9) | 72 (9.9) | 0 (0) | 77 (10.9) |
| Tolvaptan | 26 (7.3) | 17 (5.6) | 45 (5.8) | 28 (4.0) | 16 (14.7) | 9 (9.9) | 16 (2.2) | 24 (12.1) | 0 (0) |
Additionally, Supplementary Information Table S5 contained the same error. The original Table S5 and accompanying legend appear below.
Table S5
Characteristics of new users of heart failure treatment in subgroups stratified based on age and a history of prior hospitalization for heart failure.
| <75 years old (N = 833) | ≥75 years old (N = 1,902) | With prior HF hospitalization* (N = 290) | No prior HF hospitalization* (N =2,445) | |
|---|---|---|---|---|
| Age (years) | ||||
| Mean ± SD | 64.9 ± 9.3 | 82.9 ± 3.8 | 79.1 ± 9.4 | 77.2 ± 10.3 |
| Gender, male, n (%) | 567 (68.1) | 910 (47.8) | 146 (50.3) | 1,331 (54.4) |
| BNP (pg/mL) | ||||
| Patients with recorded BNP values, n (%) | 627 (75.3) | 1,381 (72.6) | 233 (80.3) | 1,775 (72.6) |
| Mean ± SD | 359.9 ± 556.8 | 381.6 ± 470.9 | 475.5 ± 481.5 | 361.7 ± 500.2 |
| BNP/NT-proBNP category, n (%) | ||||
| BNP ≤100 or NT-proBNP ≤400 pg/mL | 247 (29.7) | 294 (15.5) | 40 (13.8) | 501 (20.5) |
| 100< BNP ≤200 or 400< NT-proBNP ≤900 pg/mL | 100 (12.0) | 313 (16.5) | 42 (14.5) | 371 (15.2) |
| 200< BNP ≤300 or 900< NT-proBNP ≤2000 pg/mL | 79 (9.5) | 261 (13.7) | 44 (15.2) | 296 (12.1) |
| BNP >300 or NT-proBNP ≥2000 pg/mL | 240 (28.8) | 673 (35.4) | 134 (46.2) | 779 (31.9) |
| Missing | 167 (20.0) | 361 (19.0) | 30 (10.3) | 498 (20.4) |
| Comorbidity, n (%) | ||||
| Hypertension | 451 (54.1) | 1,089 (57.3) | 221 (76.2) | 1,319 (53.9) |
| Chronic kidney disease | 403 (48.3) | 1,086 (57.1) | 151 (52.1) | 1,338 (46.5) |
| Ischemic heart disease | 339 (40.7) | 705 (37.1) | 150 (51.7) | 894 (36.6) |
| Atrial fibrillation | 197 (23.6) | 582 (30.6) | 121 (41.7) | 658 (26.9) |
| Diabetes mellitus | 232 (27.9) | 424 (22.3) | 91 (31.4) | 565 (23.1) |
| Stroke | 93 (11.2) | 294 (15.5) | 58 (20.0) | 329 (13.5) |
| Myocardial infarction | 119 (14.3) | 200 (10.5) | 56 (19.3) | 263 (10.8) |
| Chronic obstructive pulmonary disease | 69 (8.3) | 228 (12.0) | 50 (17.2) | 247 (10.1) |
| Anemia | 154 (18.5) | 422 (22.2) | 108 (37.2) | 468 (19.1) |
| Hyperkalemia | 57 (6.8) | 142 (7.5) | 22 (7.6) | 177 (7.2) |
| Hypotension | 10 (1.2) | 28 (1.5) | 10 (3.4) | 28 (1.1) |
| HF treatments prior to the index date,** n (%) | ||||
| ACEi | 135 (16.2) | 241 (12.7) | 49 (16.9) | 327 (13.4) |
| ARB | 347 (41.7) | 728 (38.3) | 65 (22.4) | 1,010 (41.3) |
| MRA | 157 (18.8) | 304 (16.0) | 50 (17.2) | 411 (16.8) |
| Beta-blockers | 358 (43.0) | 700 (36.8) | 118 (40.7) | 940 (38.4) |
| SGLT-2i | 25 (3.0) | 34 (1.8) | 6 (2.1) | 53 (2.2) |
| Digoxin/ digitoxin | 43 (5.2) | 98 (5.2) | 8 (2.8) | 133 (5.4) |
| Loop diuretics | 406 (48.7) | 1,049 (55.2) | 155 (53.4) | 1,300 (53.2) |
| Thiazide diuretics | 57 (6.8) | 166 (8.7) | 16 (5.5) | 207 (8.5) |
| Tolvaptan | 49 (5.9) | 97 (5.1) | 18 (6.2) | 128 (5.2) |
SD, standard deviation; BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; MRA, mineralocorticoid receptor antagonist; SGLT-2i, sodium-glucose cotransporter-2 inhibitor; HF, heart failure.
* Hospitalization for HF occurred within 12 months before the index date of hospitalization. ** Used during the period of 183 days before the index date.
Finally, in the Results section, under the subheading ‘Patients characteristics’,
“Further, 60.1, 55.1, 40.9, and 28.4% of patients had hypertension, chronic kidney disease (CKD), ischemic heart disease, and atrial fibrillation, respectively.”
now reads:
“Further, 86.2, 55.9, 56.9, and 39.3% of patients had hypertension, chronic kidney disease (CKD), ischemic heart disease, and atrial fibrillation, respectively.”
The original Article and accompanying Supplementary Information files have been corrected.
Articles from Scientific Reports are provided here courtesy of Nature Publishing Group
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in Japan.
Sci Rep, 14(1):9095, 20 Apr 2024
Cited by: 0 articles | PMID: 38643208 | PMCID: PMC11032365
Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure).
Am J Cardiol, 107(12):1818-1823, 12 Apr 2011
Cited by: 45 articles | PMID: 21482418
Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults.
Cochrane Database Syst Rev, 5:CD012855, 20 May 2019
Cited by: 18 articles | PMID: 31106850 | PMCID: PMC6526465
Review Free full text in Europe PMC
The Identification of Calcified Coronary Plaque Is Associated With Initiation and Continuation of Pharmacological and Lifestyle Preventive Therapies: A Systematic Review and Meta-Analysis.
JACC Cardiovasc Imaging, 10(8):833-842, 01 Aug 2017
Cited by: 60 articles | PMID: 28797402 | PMCID: PMC5761651
Review Free full text in Europe PMC
